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The QTc interval, autonomic neuropathy and mortality 
in hypoxaemic COPD 
A. G. STEWART*, J. C. WATERHOUSE AND P. HOWARD 
Department of Medicine and Pharmacology, University of Shefield, Royal Hallamshire Hospital, 
Glossop Road, Shefield SIO 2JF, U.K. 
Patients with hypoxaemic chronic obstructive pulmonary disease (COPD) have a subclinical autonomic 
neuropathy. Autonomic neuropathy has been associated with a prolonged electrocardiograph QTc interval 
and risk of ventricular arrhythmias and death. We studied cardiovascular autonomic nerve function and QTc 
interval at rest and during stress (a valsalva manoeuvre) in 34 patients with hypoxaemic COPD who were 
followed up after 2 yr. Seventeen patients had a subclinical autonomic neuropathy (group AN) and the 
remaining 17 were normal (group C). Group AN were significantly more hypoxaemic (PaO, 7.3 f 0.3 
compared to 9.2 f 1.8, P<O.O5), had a lower FEV, and had a longer QTc at rest (0.43 % 0.01 compared to 
0.40 f 0.01, PCO.01) and at peak valsalva (044 & 0.01 compared to 0.41 f 0.01, PcO.05). 
When analysed after 2 yr, there were two deaths in group C and seven deaths in group AN. The QTc was 
abnormal ~0.44 s at rest and at peak valsalva stress in five of group AN, three of these five patients died. QTc 
was normal at rest but abnormal at peak valsalva stress in eight further patients. This included three further 
patients from group AN of whom two had died and five group C patients which included both the group C 
deaths. The presence of autonomic neuropathy and QTc prolongation (~044 s) at rest was significantly 
associated (PcO.05). Likewise QTc prolongation at the peak of a valsalva stress was significantly associated 
with death at 2 yr follow-up (P<O.Ol) with an odds ratio of 11.1. 
Patients with hypoxaemic COPD, particularly those with a parasympathetic autonomic neuropathy have 
evidence for a prolongation of the QTc interval which is associated with an increased mortality risk. 
Introduction 
We have shown that patients with hypoxaemic 
chronic obstructive pulmonary disease (COPD) have 
a subclinical autonomic neuropathy (1,2). In diabetes 
mellitus, an autonomic neuropathy is associated with 
a poor prognosis (3) and a prolonged QT interval on 
the ECG tracing (4-6). This is due to an imbalance in 
cardiac sympathetic innervation (7). Ablation of the 
right stellate ganglion or stimulation of the left 
prolong the QT interval and increase the incidence of 
ventricular arrhythmias, particularly the R on T-type 
ventricular fibrillation during myocardial ischaemia 
(7) and physical or emotional stress (8). 
Sudden death due to ventricular arrhythmias with 
an associated prolonged QT interval have been 
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reported in the congenital long QT syndrome (9), 
myocardial ischaemia (10,ll) and in diabetes mellitus 
(4,5). 
We hypothesized that severely hypoxaemic COPD 
patients would have a profound autonomic neurop- 
athy, a prolonged QT interval and a poor prognosis. 
We therefore prospectively studied the relationship 
between autonomic function, the corrected QT inter- 
val (QTc) and subsequent mortality in 40 patients 
with hypoxaemic COPD over a 2-yr period. 
Methods 
Patients within the chest clinic were clinically 
screened and those with ischaemic heart disease, 
cardiac arrhythmias (by clinical history and ECG), 
hypothyroidism, history of hypocalcaemia, those 
on drugs which prolong the QT interval (such as 
amiodarone, triludan, quinidine and tricyclic anti- 
depressants), or drugs such as digoxin which made 
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the ECG difficult to assess were excluded. Forty 
patients with only longstanding hypoxaemic COPD 
were recruited. Peripheral oedema thought to be due 
to car pulmonale was noted. 
Where possible the patients withheld p-agonists 
and ipratroprium bromide on the day of testing. 
Where this proved impossible, autonomic function 
testing and QT measurement was carried out at least 
2 h after their therapeutic usage. Diuretics were 
stopped for 3 days. 
A limb lead ECG, at 50 mm s - ’ was recorded 
after 5 min rest in a sitting position and during 
the valsalva manoeuvres. The lead which gave the 
clearest trace for measuring the RR interval (time 
between consecutive R waves on the ECG) and QT 
interval (taken from the Q wave to the end of the T 
wave) was used. Five such pairs of intervals were 
measured and averaged at rest. Likewise the QT and 
RR intervals were recorded at peak valsalva (maxi- 
mal heart rate). Three such readings were averaged. 
All tracings were analysed blind without knowledge 
of the patient involved. 
As the QT interval varies inversely with the heart 
rate, the corrected QT interval (QTc) was calculated 
using Bazetts formula: QTc= (measured QT interval)/ 
(4RR interval). 
In this study the upper limit of normal for QTc 
was taken to be 044 s, this a commonly used but 
arbitrary level (12). 
The patients were divided into those with and 
those without autonomic dysfunction by the follow- 
ing well recognized tests (1,13,14). 
Heart rate response to a valsalva manoeuvre was 
measured in seated patients after a moderate inspira- 
tion. They then blew into a mouthpiece attached to a 
sphygmomanometer and maintained a pressure of 
40 mmHg for 15 s. The patient then breathed nor- 
mally for 1 min. The valsalva ratio was calculated 
as the maximum heart rate recorded during the 
valsalva, divided by the slowest rate recorded on 
release of the valsalva. An average of three readings 
was recorded. A value less than 1.11 is abnormal 
while values greater than 1.20 are normal (1,13). 
Heart rate response to deep breathing was 
recorded in the seated patient. Heart rate was 
recorded during six deep breath cycles in 1 min. The 
I-E difference was the average of the maximum 
differences in heart rate during each breath. An I-E 
difference of less than 8 beats min ~ ’ is abnormal, 
values greater than 10 are normal in this age 
group (14). 
Heart rate and blood pressure response to standing 
was recorded after lying supine for 3 min. The patient 
stood up unaided, the heart rate response .was 
recorded and the systolic blood pressure taken at 
10-15 s after attaining the upright position. A sys- 
tolic fall greater than 30 mmHg is abnormal, a fall of 
less than 10 mmHg is deemed normal (13). The 30: 15 
ratio was the longest RR interval around beat 30 
divided by the shortest interval at beat 15. A ratio of 
less than 1.01 is abnormal and values greater than 
1.04 are normal (1,13). 
The diastolic rise in blood pressure was recorded 
during a sustained one third maximal grip on a hand 
grip dynamometer. A rise in diastolic blood pressure 
of less than 11 mmHg is abnormal whilst a rise 
greater than 16 mmHg is normal (13). 
The five tests were scored 0 if normal, 1 if 
borderline and 2 if abnormal, giving a maximum 
score of 10. Aggregate scores O-3 are normal 
while patients scoring 4 or more have an autonomic 
neuropathy. 
These patients were reviewed at regular intervals. 
At 2 yr follow-up, deaths and their circumstances 
were noted. For the three patients dying unexpect- 
edly at home, the circumstances and recent well-being 
were checked with the general practitioner and where 
possible a relative. 
Results 
It proved impossible to measure the QT interval in 
four patients, and in a further two patients frequent 
atria1 and ventricular ectopics prevented accurate 
measurement of the RR interval. These patients 
were excluded. Of the remaining 34 patients, 17 had 
an autonomic neuropathy (group AN) and were 
compared to the remaining 17 patients (group C). 
As expected (Table 1) group AN had a significantly 
worse PaO,. PaCO, and FEV, although worse in the 
autonomic group did not quite reach significance. 
When analysed at 2 yr, there were two deaths in 
group C and seven deaths in group AN. The QTc was 
abnormal (>0.44 s) at rest and at peak valsalva stress 
in five of group AN, three of these five patients had 
died. QTc was normal at rest but abnormal at peak 
valsalva stress in eight further patients. This included 
three patients from group AN of whom two had died. 
Five group C patients with normal autonomic func- 
tion had a prolonged QTc at the peak of valsalva 
manoeuvre. They included both the group C deaths. 
Two other patients with autonomic dysfunction but a 
normal QTc died. This included the only person who 
had combined (parasympathetic and sympathetic) 
neuropathy. 
By Fishers exact test (Table 2) the group with 
autonomic neuropathy had a significantly higher 
than expected number of people with a prolonged 
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Table I Baseline autonomic function in those designated control or neuropathy group (results 
as means and SEM) 
Controls 
Autonomic 
neuropathy 
Number (n) 
Age 
FEV, (1) 
PaO, (kPa) 
PaCO, (kPa) 
Valsalva ratio 
30: 15 ratio 
1-E difference 
Postural blood pressure fall 
Handgrip blood pressure rise 
History of oedema 
Number of deaths 
At rest: 
QTc 
n with QTc >0,44 
n dead at 2 yr 
During valsalva stress: 
QTc at peak valsalva 
n with QTc ~0.44 
n dead at 2 yr 
17 
64.1 (2.0) 
1.48 (0.23) 
9.2 (18)’ 7.3 (0.3)* 
59 (0.4) 6.4 (0.3) 
1.35 (0.05) 1.12 (o.ol)*** 
1.07 (0.01) 1.03 (o.ol)* 
15.5 (18) 7.2 (0.9)*** 
8 (1.8) 11.7 (3.5) 
21.4(1.5) 15.5 (1.2)** 
0.17 11117 
2117 7117 
0.40 (0.01) 
0 
0 
0.41 (0.01) 
5 
215 
17 
64.1 (1.5) 
0.94 (0,101 
0.43 (o.ol)** 
5 
315 
044 (o.ol)* 
8 
5/8 
*P<O.O5, **P<O.Ol, ***P<O.OOl (Mann-Whitney U) 
Tub/e 2 Autonomic neuropathy, QTc prolongation and death at 2 yr in patients with 
hypoxaemic COPD (Fishers exact test) 
Dead 
Alive 
Autonomic 
neuropathy Normal 
7 2 
10 15 
P=O.O5 
Autonomic neuropathy and prolonged QTc 
At rest 
Autonomic 
neuropathy Normal 
Peak valsalva 
Autonomic 
neuropathy Normal 
QTc >044 
QTc co.44 
5 0 
12 17 
PCO.05 
QTc prolongation and death at 2 yr 
At rest 
Dead Alive 
QTc >044 
QTc ~044 
8 5 
9 12 
P NS 
Peak valsalva 
Dead Alive 
QTc ~0.44 
QTc ~0.44 
3 2 
6 23 
P=O.O6 NS 
QTc >044 
QTc ~0.44 
7 6 
2 19 
PCO.01 
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Fig. I Hierarchical log-linear modelling. -, PcO.05; =, PcO.01; =, P<O.OOl. 
QTc at rest but not at peak valsalva. Those patients 
with a prolonged QTc at peak valsalva had a greater 
than expected death rate (P<O.Ol). Only patients 
with evidence for autonomic neuropathy had current 
or a history of oedema (P<O.OOl). 
Multiple logistic regression analysis with forward 
steps confirmed the importance of a prolonged QTc 
interval during a valsalva stress in prediction of sub- 
sequent death (P<O.Ol) with an odds ratio of 11.1. 
After removal of this term from the model, no other 
variable (e.g. presence of oedema, arterial oxygen 
tension less than 8 kPa, FEV, less than 1 1, presence 
of autonomic neuropathy) reached significance due to 
the small number of patients in this study. 
Hierarchical log-linear modelling suggested the 
relationship shown in Fig. 1. Although the inter- 
actions were significant, the relatively small numbers 
involved in this study make it mandatory for this to 
be repeated in a much larger number of patients. 
Discussion 
QTc prolongation does occur in hypoxaemic 
COPD and is more common in those patients with an 
autonomic neuropathy. However a prolonged QTc 
can occur during physical stress without electro- 
physiological evidence of an autonomic neuropathy. 
Prolongation of QTc was a better predictor of 
death than the presence of autonomic neuropathy, 
oedema, hypoxaemia, hypercapnia or impairment in 
spirometry. A prolonged (co.44 s) QTc after the 
stress of a valsalva manoeuvre gave an odds ratio of 
11.1. The death rate was much greater than that 
reported for prolonged QTc after myocardial infarc- 
tion (10) and in diabetes (4). The high death rate 
(9/34) might reflect the severity of respiratory failure 
in the patients chosen for this study. Even so, four of 
the patients who died were leading a reasonably 
active life at the time of recruitment. 
In this study, the autonomic neuropathy group 
suffered seven deaths out of 17 members. This is 
comparable to 50% mortality at 2.5 yr reported in 
diabetics with autonomic neuropathy (15). However 
as in this study, the deaths were not necessarily due to 
autonomic neuropathy per se. Selection of patients 
for this study was not randomized. The patients 
tended to have worse chest disease than other 
members of the clinic as shown by their regular and 
often long term follow up. Many of them had had 
frequent recurrent hospital admissions mostly with 
oedematous car pulmonale and therefore had a poor 
prognosis. 
Only three patients died relatively unexpectedly at 
home. The rest died during hospitalization and treat- 
ment for infective exacerbations of their COPD. 
Arrhythmias were not noted (or excluded) as the 
terminal event, most of the deaths were expected in 
patients with terminal respiratory failure refractory 
to standard therapy. 
In the Rotterdam QT project of 6693 patients, 
those patients without cardiac dysfunction whose 
QTc was greater than 0.44 s had a relative risk of 
sudden death of 2.3 compared to those whose QTc 
was less than 0.44 s. The Rotterdam study noted that 
cigarette smokers comprised 35% of the group with a 
prolonged QTc but only 12% of the group with a 
normal QTc. Unfortunately the relationship between 
death, COPD, ischaemic heart disease and smoking 
was not studied (16). 
The relevance of QTc prolongation and its 
potential for ventricular fibrillation needs further 
evaluation. Maladapted responses to heart rate 
increases during hypoxaemia could lead to fatal 
arrhythmias. Death is more common at night in 
COPD patients with hypoxaemia and hypercapnia 
than in an age matched cohort (17). Although 
patients with COPD have an increased frequency 
of premature ventricular complexes, overnight 
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monitoring suggests that cardiac dysrhythmias are a 
relatively uncommon complication of nocturnal 
desaturation (18). However, it is possible that 
severely ill COPD patients have not been monitored 
for long enough to pick up the small number of life 
threatening ventricular arrhythmias. Arrhythmias 
may only occur when there is an additional precipi- 
tant such as hypoxia or hypokalaemia-two 
pertinent risk factors in patients with COPD. A 
similar lack of evidence for increased ventricular 
arrhythmia rate exists in diabetes mellitus (19). How- 
ever QT prolongation is associated with ventricular 
arrhythmias and sudden death in myocardial 
ischaemia (10). 
The common occurrence of autonomic neuropathy 
and QTc prolongation in a wide variety of diseases 
[congenital QT (7), diabetes (4-6) myocardial infarc- 
tion (S)] suggest that the two are somehow linked. 
This may be due to a sympathetic imbalance and 
could be studied further by meta-iodobenzyl- 
guanidine scintigraphy (4). 
Prolongation of the QTc is believed to be due to an 
imbalance in the sympathetic drives from the right 
and left stellate ganglia. The sympathetic tests used in 
this study are fairly insensitive and failed to show a 
significant degree of sympathetic neuropathy. This 
does not exclude the possibility that these patients 
might have such a sympathetic imbalance, as most 
sympathetic neuropathies are patchy. 
Although the parasympathetic nerves may not 
affect the QTc interval they are important in reducing 
the occurrence of sudden death and ventricular 
fibrillation after myocardial infarction in dogs (20). 
Parasympathetic cardiac denervation may therefore 
increase the risk of sudden death during sympathetic 
stimulation. Loss of vagal tone would magnify any 
sympathetic imbalances. As heart rate quickens vagal 
tone tends to slow its rate of rise and thus protects 
those people whose rate of QTc shortening is slow 
from the risk of an R on T phenomenon arrhythmia. 
Furthermore loss of vagal tone causes a tachycardia 
even at rest. The coexistence of a short RR with a 
long QT greatly increases the risk of R on T phenom- 
enon with subsequent ventricular fibrillation. 
Although studies in diabetes suggest that QTc 
prolongation is due to autonomic neuropathy rather 
than diabetes per se (4,13,15) the actual mechanism is 
unknown. As in COPD, diabetic autonomic neurop- 
athy is primarily a parasympathetic loss with later 
sympathetic imbalance. 
Since this study was started there has been contro- 
versy over the possible role of &agonists and 
increasing death rates from asthma (21). Nebuliz- 
ation of B-agonists particularly fenoterol seemed to 
be related to risk of death. This was associated with a 
greater increase in heart rate, a greater degree of 
hypokalaemia, and a greater prolongation of the QTc 
interval post nebulization (22). As none of the 
patients in this study were receiving nebulized fenot- 
erol and as autonomic function testing was always 
carried out at least 2 h after p-agonist therapy, it is 
difficult to relate these findings to this study. The 
small increases in QTc noted would not explain the 
differences between our two groups. It is unlikely 
that therapy is the sole explanation for the results. 
However, it is essential that future studies on the 
QTc interval are performed with tight control of 
therapy (previous, current and future) to examine the 
inter-relationships between &-agonists, QTc and 
autonomic nerve function. It is possible that people 
with a prolonged stress QTc (particularly those with 
autonomic dysfunction) might be at greater risk of 
a fatal arrhythmia during high dose nebulized 
&agonists. 
In conclusion, patients with hypoxaemic COPD 
have a subclinical autonomic neuropathy and a 
prolonged QTc. Those patients with COPD and a 
prolonged stress QTc interval are at a greater risk of 
death. QTc prolongation is most likely in those 
patients with evidence for a subclinical autonomic 
neuropathy. These simple tests might help to pick out 
a high risk group in whom therapeutic intervention 
such as earlier oxygen therapy especially for noctur- 
nal or exercise hypoxaemia might be beneficial. It 
might also identify those patients who are at risk 
from therapies causing heart rate changes, pro- 
longation of QTc and hypokalaemia. Measurement 
of simple autonomic function and QTc intervals 
might identify patients at risk during anaesthesia, 
septicaemia or hypoxaemia. Such knowledge should 
ensure appropriate remedial action and thus 
improve life expectancy in patients with hypoxaemic 
COPD. 
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